Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Inventory (2020 - 2026)

Cytek Biosciences filings provide 6 years of Inventory readings, the most recent being $48.4 million for Q4 2025.

  • On a quarterly basis, Inventory rose 10.33% to $48.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.4 million, a 10.33% increase, with the full-year FY2025 number at $48.4 million, up 10.33% from a year prior.
  • Inventory hit $48.4 million in Q4 2025 for Cytek Biosciences, down from $51.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $69.5 million in Q1 2023 to a low of $26.7 million in Q2 2021.
  • Median Inventory over the past 5 years was $48.4 million (2025), compared with a mean of $48.5 million.
  • Biggest five-year swings in Inventory: soared 82.99% in 2023 and later tumbled 30.02% in 2024.
  • Cytek Biosciences' Inventory stood at $32.2 million in 2021, then skyrocketed by 49.68% to $48.2 million in 2022, then rose by 26.42% to $60.9 million in 2023, then dropped by 27.9% to $43.9 million in 2024, then increased by 10.33% to $48.4 million in 2025.
  • The last three reported values for Inventory were $48.4 million (Q4 2025), $51.6 million (Q3 2025), and $49.5 million (Q2 2025) per Business Quant data.